These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 24481929)
1. Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program. Shah PA; Sohler NL; López C; Fox AD; Cunningham CO J Opioid Manag; 2013; 9(6):407-13. PubMed ID: 24481929 [TBL] [Abstract][Full Text] [Related]
2. Consumer attitudes about opioid addiction treatment: a focus group study in New York City. Sohler NL; Weiss L; Egan JE; López CM; Favaro J; Cordero R; Cunningham CO J Opioid Manag; 2013; 9(2):111-9. PubMed ID: 23709320 [TBL] [Abstract][Full Text] [Related]
3. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. Fox AD; Chamberlain A; Sohler NL; Frost T; Cunningham CO J Subst Abuse Treat; 2015 Jan; 48(1):112-6. PubMed ID: 25205666 [TBL] [Abstract][Full Text] [Related]
4. I heard about it from a friend: assessing interest in buprenorphine treatment. Fox AD; Shah PA; Sohler NL; Lopez CM; Starrels JL; Cunningham CO Subst Abus; 2014; 35(1):74-9. PubMed ID: 24588297 [TBL] [Abstract][Full Text] [Related]
5. Treatment readiness, attitudes toward, and experiences with methadone and buprenorphine maintenance therapy among people who inject drugs in Malaysia. Vijay A; Bazazi AR; Yee I; Kamarulzaman A; Altice FL J Subst Abuse Treat; 2015 Jul; 54():29-36. PubMed ID: 25841703 [TBL] [Abstract][Full Text] [Related]
6. Opioid dependent patients' experiences of and attitudes towards having their injecting sites examined. Winstock AR; Nittis M; Whitton G; Lea T Int J Drug Policy; 2009 Jan; 20(1):85-9. PubMed ID: 18164193 [TBL] [Abstract][Full Text] [Related]
7. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia. Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093 [TBL] [Abstract][Full Text] [Related]
8. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. Winstock AR; Lea T; Sheridan J Int J Drug Policy; 2008 Dec; 19(6):450-8. PubMed ID: 18359216 [TBL] [Abstract][Full Text] [Related]
9. Addressing the opioid crisis: An assessment of clinicians' training experience, practices, and attitudes within a large healthcare organization. Kirane H; Drits E; Ahn S; Kapoor S; Morgenstern J; Conigliaro J; Enden J J Opioid Manag; 2019; 15(3):193-204. PubMed ID: 31343721 [TBL] [Abstract][Full Text] [Related]
10. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. Bachhuber MA; Thompson C; Prybylowski A; Benitez J; Mazzella S; Barclay D Subst Abus; 2018; 39(2):167-172. PubMed ID: 29474119 [TBL] [Abstract][Full Text] [Related]
11. High risk and little knowledge: overdose experiences and knowledge among young adult nonmedical prescription opioid users. Frank D; Mateu-Gelabert P; Guarino H; Bennett A; Wendel T; Jessell L; Teper A Int J Drug Policy; 2015 Jan; 26(1):84-91. PubMed ID: 25151334 [TBL] [Abstract][Full Text] [Related]
13. Buprenorphine misuse among heroin and amphetamine users in Malmo, Sweden: purpose of misuse and route of administration. Hakansson A; Medvedeo A; Andersson M; Berglund M Eur Addict Res; 2007; 13(4):207-15. PubMed ID: 17851242 [TBL] [Abstract][Full Text] [Related]
14. The Perceived Role of Withdrawal in Maintaining Opioid Addiction among Adults with Untreated Opioid Use Disorder: A Survey of Syringe Exchange Program Participants. Hall OT; Entrup P; Farabee K; Qin H; Rizvi H; Rausch J; Felkel WC; Teater J Subst Use Misuse; 2024; 59(2):312-315. PubMed ID: 37861246 [No Abstract] [Full Text] [Related]
15. Buprenorphine prescribing practice trends and attitudes among New York providers. Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694 [TBL] [Abstract][Full Text] [Related]
16. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations. Stancliff S; Joseph H; Fong C; Furst T; Comer SD; Roux P J Addict Dis; 2012; 31(3):278-87. PubMed ID: 22873189 [TBL] [Abstract][Full Text] [Related]
17. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications. Bruce RD; Dvoryak S; Sylla L; Altice FL Int J Drug Policy; 2007 Aug; 18(4):326-8. PubMed ID: 17689382 [TBL] [Abstract][Full Text] [Related]
18. Injecting misuse of buprenorphine among French drug users. Obadia Y; Perrin V; Feroni I; Vlahov D; Moatti JP Addiction; 2001 Feb; 96(2):267-72. PubMed ID: 11182872 [TBL] [Abstract][Full Text] [Related]
19. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia. Geddes L; Iversen J; Wand H; Maher L Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931 [TBL] [Abstract][Full Text] [Related]
20. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study. Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]